Is the autophagy induced by thiopurines beneficial or deleterious?

Current Drug Metabolism

Volumn 13, Issue 9, 2012, Pages 1267-1276

  Guijarro, Luis G ^a   Román, Irene D ^a   Fernández Moreno, M Dolores ^a   Gisbert, Javier P ^b   Hernández Breijo, Borja ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

6 thioguanine; Atg; Autophagosome; Azathioprine; Hepatotoxicity; Lysosome; MTOR

Indexed keywords

ADENOSINE TRIPHOSPHATE; AZATHIOPRINE; GUANOSINE PHOSPHATE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INOSINATE DEHYDROGENASE; MERCAPTOPURINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P53; S6 KINASE; STRESS ACTIVATED PROTEIN KINASE; TIOGUANINE; XANTHINE OXIDASE;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOLYSOSOME; BONE MARROW TOXICITY; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CHAPERONE-MEDIATED AUTOPHAGY; DNA CROSS LINKING; DNA DAMAGE; DOSE RESPONSE; DRUG HALF LIFE; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; LEUKEMIA; LEUKOPENIA; LIVER CELL; LIVER TOXICITY; MACROAUTOPHAGY; MICROAUTOPHAGY; MISMATCH REPAIR; NONHUMAN; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; PANCREATITIS; PANCYTOPENIA; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; AUTOPHAGY; HUMANS; PURINES;

EID: 84868020161     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012803341366     Document Type: Review

References (71)

1. Cara, C.J.; Pena, A.S.; Sans, M.;, Rodrigo, L.; Guerrero-Esteo, M.; Hinojosa, J.; García-Paredes, J.; Guijarro, LG. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med. Sci. Monit., 2004, 10(11), RA247-254.
2. Murray, J.E.; Merril, J.P.; Harrison, J.H.; Wilson, R.E.; Dammin, G.J. Prolonged survival of human-kidney homografts by immuno-suppressive drug therapy. N. Engl. J. Med., 1963, 268, 1315-1323.
3. Schold, J.D.; Kaplan, B. AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. Am. J. Transplan., 2009, 9(9), 2067-2074.
4. Denfield, S.W. Strategies to prevent cellular rejection in pediatric heart transplant recipients. Paediatr. Drugs, 2010, 12(6), 391-403.
5. Starzl, T.E.; Fung, J.J. Themes of liver transplantation. Hepatology, 2010, 51(6), 1869-1884.
6. Clarke, D.A.; Philips, F.S.; Sternberg, S.S.; Stock, C.C.; Elion; G.B,; Hitchings, G.H. 6-Mercaptopurine: effects in mouse sarcoma 180 and in normal animals. Cancer Res., 1953, 13(8), 593-604.
7. Burchenal, J.H.; Murphy, M.L.; Ellison, R.R.; Sykes, M.P.; Tan, T.C.; Leone, L.A.; Karnofsky, D.A.; Craver, L.F.; Dargeon, H.W.; Rhoads, C.P. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood, 1953, 8(11), 965-999.
8. Swidsinski, A.; Loening-Baucke, V.; Bengmark, S.; Lochs, H.; Dörffel, Y. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm Bowel Dis., 2007, 13(1), 51-56.
9. Arnott, I.D.; Watts, D.; Satsangi. J. Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol. Res., 2003, 47(1), 1-10.
10. Panaccione, R.; Rutgeerts, P.; Sandborn, W.J.; Feagan, B.; Schreiber, S.; Ghosh, S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol. Ther., 2008, 28(6), 674-688.
11. Rahhal, R.M.; Bishop, W.P. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm. Bowel Dis., 2008, 14(12), 1678-1682.
12. Rogler, G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract. Res. Clin. Gastroenterol., 2010, 24(2), 157-165.
13. Eklund, B.I.; Moberg, M.; Bergquist, J.; Mannervik, B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol. Pharmacol., 2006, 70(2), 747-754.
14. Tiede, I.; Fritz, G.; Strand, S; Poppe, D.; Dvorsky, R.; Strand, D.; Lehr, H.A.; Wirtz, S.; Becker, C.; Atreya, R.; Mudter, J.; Hildner, K.; Bartsch, B.; Holtmann, M.; Blumberg, R.; Walczak, H.; Iven, H.; Galle, P.R.; Ahmadian, M.R.; Neurath, M.F. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest., 2003, 111(8), 1133-1145.
15. Tay, B.S.; Lilley, R.M.; Murray, A.W.; Atkinson, M.R. Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. Biochem. Pharmacol., 1969, 18(4), 936-938.
16. Elion, G.B. The purine path to chemotherapy. Science, 1989, 244(4900), 41-47.
17. Wang, H.; Wang, Y. 6-Thioguanine perturbs cytosine methylation at the CpG dinucleotide site by DNA methyltransferases in vitro and acts as a DNA demethylating agent in vivo. Biochemistry, 2009, 48(10), 2290-2299.
18. Christie, N.T.; Drake, S.; Meyn, R.E.; Nelson, J.A. 6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. Cancer Res., 1984, 44(9), 3665-3671.
19. Pan, B.F.; Nelson, JA. Characterization of the DNA damage in 6-thioguanine-treated cells. Biochem. Pharmacol., 1990, 40(5), 1063-1069.
20. Bodell, W.J. Molecular dosimetry of sister chromatid exchange induction in 9L cells treated with 6-thioguanine. Mutagenesis, 1991, 6(3), 175-177.
21. Swann, P.F.; Waters, T.R.; Moulton, D.C.; Xu, Y.Z.; Zheng, Q.; Edwards, M.; Mace, R. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science, 1996, 273(5278),1109-1111.
22. Stojic, L.; Brun, R.; Jiricny, J. Mismatch repair and DNA damage signalling. DNA Repair (Amst), 2004, 3(8-9), 1091-1101.
23. Zeng, X.; Yan, T.; Schupp, J.E.; Seo, Y.; Kinsella, T.J. DNA mismatch repair initiates 6-thioguanine - induced autophagy through p53 activation in human tumor cells. Clin. Cancer Res., 2007, 13(4), 1315-1321.
24. Zeng, X.; Kinsella, T.J. Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy. Cancer Res., 2008, 68(7), 2384-2390.
25. Hernández-Breijo, B.; Monserrat, J.; González-Rodriguez, A.; Fernández-Moreno, M.D.; Román, I.D.; Álvarez de Mon, M.; Val-verde, A.M.; Gisbert, J.P.; Guijarro, L.G. Azathioprine produces autophagy through ERK/mTOR/P70S6K pathway in HepG2 cells. J. Hepatol., 2011, 54(S1), S202.
26. Glick, D.; Barth, S.; Macleod, K.F. Autophagy: cellular and molecular mechanisms. J. Pathol., 2010, 221(1), 3-12.
27. Rabinowitz, J.D.; White, E. Autophagy and metabolism. Science, 2010, 330(6009). 1344-1348.
28. Levine, B.; Kroemer, G. Autophagy in the Pathogenesis of Disease. Cell, 2008, 132(1), 27-42.
29. Klionsky, D.J. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat. Rev. Mol. Cell Biol., 2007, 8(11), 931-937.
30. Mizushima, N., Klionsky, D.J. Protein turnover via autophagy: implications for metabolism. Annu. Rev. Nutr., 2007, 27, 19-40.
31. Maiuri, M.C.; Zalckvar, E.; Kimchi, A.; Kroemer, G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol., 2007, 8(9), 741-752.
32. Yin, X.M.; Ding, W.X.; Gao, W. Autophagy in the liver. Hepatology, 2008, 47(5), 1773-1785.
33. Kaser, A.; Blumberg, R.S. Autophagy, Microbial Sensing, Endoplasmic Reticulum Stress, and Epithelial Function in Inflammatory Bowel Disease. Gastroenterology, 2011, 140(6), 1738-1747.
34. Cuervo, A.M. Chaperone-mediated autophagy: selectivity pays off. Trends Endocrinol. Metab., 2010, 21(3), 142-150.
35. Mizushima, N.; Levine, B.; Cuervo, A.M.; Klionsky, D.J. Autophagy fights disease through cellular self-digestion. Nature, 2008, 451(7182), 1069-1075.
36. Santambrogio, L.; Cuervo, A.M. Chasing the elusive mammalian microautophagy. Autophagy, 2011, 7(6), 1-3.
37. Li, W.; Yang, Q.; Mao, Z. Chaperone-mediated autophagy: machinery, regulation and biological consequences. Cell. Mol. Life Sci., 2011, 68(5), 749-763.
38. Klionsky, D.J.; Cregg, J.M.; Dunn, W.A. Jr.; Emr, S.D.; Sakai, Y.; Sandoval, I.V.; Sibirny, A.; Subramani, S.; Thumm, M.; Veenhuis, M.; Ohsumi, Y. A unified nomenclature for yeast autophagyrelated genes. Dev Cell, 2003, 5(4), 539-545.
39. Kawaguchi, T.; Miyazawa, K.; Moriya, S.; Ohtomo, T.; Che, X.F.; Naito, M.; Itoh, M.; Tomoda, A. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. Int. J. Oncol., 2011, 38(3), 643-654.
40. Gibbons, J.J; Abraham, R.T.; Yu, K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol., 2009, 36(S3), S3-S17.
41. Wang, R.C.; Levine, B. Autophagy in cellular growth control. FEBS Lett., 2010, 584(7), 1417-1426.
42. Stephan, J.S.; Yeh, Y.Y.; Ramachandran, V.; Deminoff, S.J.; Herman, P.K. The Tor and PKA signaling pathways independently target the Atg1/Atg13 protein kinase complex to control autophagy. Proc. Natl. Acad. Sci USA, 2009, 106(40), 17049-17054.
43. Chang, Y.Y.; Neufeld, T.P. An Atg1/Atg13 complex with multiple roles in TOR-mediated autophagy regulation. Mol. Biol. Cell, 2009, 20(7), 2004-2014.
44. Young, A.R.; Chan, E.Y.; Hu, X.W.; Kochl, R.; Crawshaw, S.G.; High, S.; Hailey, D.W.; Lippincott-Schwartz, J.; Tooze, S.A. Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes. J. Cell Sci., 2006, 119(Pt18), 3888-3900.
45. Kanematsu, S.; Uehara, N.; Miki, H.; Yoshizawa, K.; Kawanaka, A.; Yuri, T.; Tsubura, A. Autophagy inhibition enhances sulforaphane-induced apoptosis in human breast cancer cells. Anticancer Res., 2010, 30(9), 3381-3390.
46. Chen, R.J.; Ho, C.T.; Wang, Y.J. Pterostilbene induces autophagy and apoptosis in sensitive and chemoresistant human bladder cancer cells. Mol. Nutr. Food Res., 2010, 54(12), 1819-1832.
47. Zhao, Q.L.; Fujiwara, Y.; Kondo, T. Synergistic induction of apoptosis and caspase-independent autophagic cell death by a combination of nitroxide Tempo and heat shock in human leukemia U937 cells. Apoptosis, 2010, 15(10), 1270-1283.
48. Gozuacik, D.; Kimchi, A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene, 2004, 23, 2891-2906.
49. Sandborn, W.J. Azathioprine: state of the art in inflammatory bowel disease. Scand J. Gastroenterol. Suppl., 1998, 225, 92-99.
50. Hawwa, A.F.; Millership, J.S.; Collier, P.S.; Vandenbroeck, K.; McCarthy, A.; Dempsey, S.; Cairns, C.; Collins, J.; Rodgers, C.; McElnay, J.C. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J. Clin. Pharmacol., 2008, 66(4), 517-528.
51. Gisbert, J.P.; Niño, P.; Rodrigo, L.; Cara, C.; Guijarro, L.G. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am. J. Gastroenterol., 2006, 101(12), 2769-2776.
52. Li, F.; Wang, L.; Burgess, R.J.; Weinshilboum, R.M. Thiopurine Smethyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. Pharmacogenet. Genomics, 2008, 18(12), 1083-1094.
53. Best, C.; Sudel, B. Bone marrow suppression in the setting of normal thiopurine methyltransferase phenotype testing. Clin. Pediatr. (Phila), 2010, 49(9), 901-903.
54. Kwan, L.Y.; Devlin, S.M.; Mirocha, J.M.; Papadakis, K.A. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Dig. Liver Dis., 2008, 40(6), 425-432.
55. Feng, Q.; Vannaprasaht, S.; Peng, Y.; Angsuthum, S.; Avihingsanon, Y.; Yee, V.C.; Tassaneeyakul, W.; Weinshilboum, R.M. Thiopurine S-methyltransferase pharmacogenetics: Functional characterization of a novel rapidly degraded variant allozyme. Biochem. Pharmacol., 2010, 79(7), 1053-1061.
56. Wang, L.; Weinshilboum, R.M. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene, 2006, 25(11), 1629-38.
57. de Boer, N.K.; Mulder, C.J.; van Bodegraven, A.A. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth. J. Med., 2005, 63(11), 444-446.
58. Dubinsky, M.C.; Lamothe, S.; Yang, H.Y.; Targan, S.R.; Sinnett, D.; Théorêt, Y.; Seidman, E.G. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology, 2000, 118(4), 705-713.
59. Fraser, A.G.; Orchard, T.R.; Jewell, D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut, 2002, 50(4), 485-489.
60. Schwab, M.; Schäffeler, E.; Marx, C.; Fischer, C.; Lang, T.; Behrens, C.; Gregor, M.; Eichelbaum, M.; Zanger, U.M.; Kaskas, B.A. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine Smethyltransferase polymorphism. Pharmacogenetics, 2002, 12(6), 429-436.
61. Bastida, G.; Nos, P.; Aguas, M.; Beltrán, B.; Rubín, A.; Dasí, F.; Ponce, J. Incidence, risk factors and clinical course of thiopurineinduced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol. Ther., 2005, 22(9), 775-782.
62. Vernier-Massouille, G.; Cosnes, J.; Lemann, M.; Marteau, P.; Reinisch, W.; Laharie, D.; Cadiot, G.; Bouhnik, Y.; De Vos, M.; Boureille, A.; Duclos, B.; Seksik, P.; Mary, J.Y.; Colombel, J.F. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut, 2007, 56(10), 1404-1409.
63. Dubinsky, M.C.; Vasiliauskas, E.A.; Singh, H.; Abreu, M.T.; Papadakis, K.A.; Tran, T.; Martin, P.; Vierling, J.M.; Geller, S.A.; Targan, S.R.; Poordad, F.F. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology, 2003, 125(2), 298-303.
64. Gardiner, S.J.; Gearry, R.B.; Burt, M.J.; Ding, S.L.; Barclay, M.L. Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur. J. Gastroenterol. Hepatol., 2008, 20(12), 1238-1242.
65. Petit, E.; Langouet, S.; Akhdar, H.; Nicolas-Nicolaz, C.; Guillouzo, A.; Morel, F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol. In vitro, 2008, 22(3), 632-642.
66. Menor, C.; Fernández-Moreno, M.D.; Fueyo, J.A.; Escribano, O.; Olleros, T.; Arriaza, E.; Cara, C.; Lorusso, M.; Di Paola, M.; Román, I.D.; Guijarro, L.G. Azathioprine acts upon rat hepatocyte mitochondria and stress-activated protein kinases leading to necrosis: protective role of N-acetyl-L-cysteine. J. Pharmacol. Exp. Ther., 2004, 311(2), 668-676.
67. Coulthard, S.A.; Hogarth, L.A.; Little, M.; Matheson, E.C.; Redfern, C.P.; Minto, L.; Hall, A.G. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol. Pharmacol., 2002, 62(1):102-109.
68. Lee, A.U.; Farrell, G.C. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. J. Hepatol., 2001, 35(6), 756-764.
69. Tapner, M.J.; Jones, B.E.; Wu, W.M.; Farrell, G.C. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J. Hepatol., 2004, 40(3), 454-463.
70. Wang, J.; Whiteman, M.W.; Lian, H.; Wang, G.; Singh, A.; Huang, D.; Denmark, T. A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1. J. Biol. Chem., 2009, 284(32), 21412-21424.
71. Magami, Y.; Azuma, T.; Inokuchi, H.; Kokuno, S.; Moriyasu, F.; Kawai, K.; Hattori, T. Cell proliferation and renewal of normal he-patocytes and bile duct cells in adult mouse liver. Liver, 2002, 22(5), 419-425.